The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
Open accessAbstract
Despite remarkable improvements in cancer treatment approaches, breast cancer is still the main cause of cancer-related death in women. Its principal cause is the resistance of the cancer cells against conventional anticancer therapeutics, mainly in advanced disease stages. It has been shown that chronic inflammation in the tumor microenvironment facilitates tumor growth and induces resistance toward chemo- and radiotherapy. Overexpression of interleukin-6 (IL-6) cytokine in the tumor microenvironment has been demonstrated in numerous tumors including breast cancer. Tumor cells and tumor-associated fibroblasts are the major sources of IL-6 secretion in the tumor microenvironment. Several studies have demonstrated the immunopathogenic function of IL-6 and its signaling in the tumor growth, metastasis, and therapeutic resistance in the breast cancer. Therefore, it seems that targeting IL-6 and/or its receptor in combination with other potent anticancer therapies may be a potent therapeutic approach for breast cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-6 is also a key factor in inflammation, autoimmunity and cancer, with its effect mainly exerted through the IL-6–signal transducer and activator of transcription 3 (STAT3) pathway (18–26, 61–65).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,719
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Harbeck, N., & Gnant, M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,466
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,214
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,207
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S. R., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,132
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Adult Weight Change and Risk of Postmenopausal Breast Cancer
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M., Grady, D., Kornitzer, M., Mcnabb, M., & Wenger, N. (2006) · New England Journal of Medicine · doi:10.1097/01.aog.0000240891.17534.ad · Cited by 754
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 693
The two faces of IL-6 in the tumor microenvironment
Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693
Hirano, T., Taga, T., Nakano, N., Yasukawa, K., Kashiwamura, S., Shimizu, K., Nakajima, K., Pyun, K., & Kishimoto, T. (1985) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.82.16.5490 · Cited by 691
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose‐John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 689
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M. S. C., & Yao, Y. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 677
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M., & Rose-John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 665
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H. D., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 594
Nakajima, T., Kinoshita, S. M., Sasagawa, T., Sasaki, K., Naruto, M., Kishimoto, T., & Akira, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2207 · Cited by 573
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Bromberg, J., & Wang, T. C. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.009 · Cited by 570
Körkaya, H., Kim, G.-I., Davis, A., Malik, F. A., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R. C., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 546
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Interleukin-6 - A Key Regulator of Colorectal Cancer Development
Waldner, M. J., Foersch, S., & Neurath, M. F. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4614 · Cited by 434
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
Klein, B., Wijdenes, J., Zhang, X.-X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clément, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.bloodjournal7851198 · Cited by 432
Targeting STAT3 in cancer: how successful are we?
Yue, P.-B., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 425
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J.-M., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 417
Plasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller‐Newen, G., Grötzinger, J., Rose‐John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 409
Nagasaki, T., Hara, M., Nakanishi, H., Takahashi, H., Sato, M., & Takeyama, H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.748 · Cited by 401
Cytokine and cytokine receptor gene polymorphisms and their functionality
Smith, A. J. P., & Humphries, S. E. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.006 · Cited by 374
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Grivennikov, S. I., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.020 · Cited by 373
The role of intratumoral and systemic IL-6 in breast cancer
Dethlefsen, C., Højfeldt, G. W., & Højman, P. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2488-z · Cited by 372
Oestrogen receptor negative breast cancers exhibit high cytokine content
Chavey, C., Bibeau, F., Gourgou-Bourgade, S., Burlinchon, S., Boissière, F., Laune, D., Roques, S., & Lazennec, G. (2007) · Breast Cancer Research · doi:10.1186/bcr1648 · Cited by 357
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 329
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose‐John, S., & Scheller, J. (2010) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 298
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 288
Purohit, A., Newman, S. P., & Reed, M. (2002) · Breast Cancer Research · doi:10.1186/bcr425 · Cited by 256
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Bayliss, T. J., Smith, J., Schuster, M. K., Dragnev, K. H., & Rigas, J. R. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.627850 · Cited by 250
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Kontzias, A., Kotlyar, A. M., Laurence, A. D. J., Changelian, P. S., & O’Shea, J. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.008 · Cited by 237
Dorff, T., Goldman, B., Pinski, J., Mack, P., Lara, P., Veldhuizen, P. V., Quinn, D., Vogelzang, N., Thompson, I., & Hussain, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 219
Kurzrock, R., Voorhees, P., Casper, C., Furman, R., Fayad, L., Lonial, S., Borghaei, H., Jagannath, S., Sokol, L., Usmani, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3349 · Cited by 202
The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance
Duong, M. N., Geneste, A., Fallone, F., Li, X., Dumontet, C., & Muller, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18038 · Cited by 198
Ricciardi, M., Zanotto, M., Malpeli, G., Bassi, G., Perbellini, O., Chilosi, M., Bifari, F., & Krampera, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.29 · Cited by 188
Chang, C.-H., Hsiao, C.-F., Yeh, Y.-M., Chang, G., Tsai, Y.-H., Chen, Y.-M., Huang, M.-S., Chen, H.-L., Li, Y.-J., Yang, P.-C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27892 · Cited by 187
Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
Čulig, Z., & Puhr, M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.033 · Cited by 179
Jadidi-Niaragh, F., Atyabi, F., Rastegari, A., Kheshtchin, N., Arab, S., Hassannia, H., Ajami, M., Mirsanei, Z., Habibi, S., Masoumi, F., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.012 · Cited by 174
Self-citationLi, H., Xiao, H., Lin, L., Jou, D., Kumari, V., Lin, J., & Li, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401144z · Cited by 167
Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Oh, K., Lee, O.-Y., Shon, S.-Y., Nam, O., Ryu, P. M., Seo, M. W., & Lee, D. (2013) · Breast Cancer Research · doi:10.1186/bcr3473 · Cited by 160
Madden, K. S., Szpunar, M. J., & Brown, E. B. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1348-y · Cited by 156
Blücher, C., & Stadler, S. C. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00293 · Cited by 155
Voorhees, P. M., Manges, R., Sonneveld, P., Jagannath, S., Somlo, G., Krishnan, A. Y., Lentzsch, S., Frank, R. C., Zweegman, S., Wijermans, P., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12266 · Cited by 149
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
Kazemi, M. H., Mohseni, S. R., Hojjat‐Farsangi, M., Anvari, E., Ghalamfarsa, G., Mohammadi, H., & Jadidi‐Niaragh, F. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25873 · Cited by 149
Self-citationBarbieri, I., Pensa, S., Pannellini, T., Quaglino, E., Maritano, D., Demaria, M., Voster, A., Turkson, J., Cavallo, F., Watson, C. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2840 · Cited by 148
Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies
Raggi, C., Mousa, H. S., Correnti, M., Sica, A., & Invernizzi, P. (2015) · Oncogene · doi:10.1038/onc.2015.132 · Cited by 148
Gyamfi, J., Lee, Y.-H., Eom, M., & Choi, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27184-9 · Cited by 144
Cancer-associated adipocytes promotes breast tumor radioresistance
Bochet, L., Meulle, A., Imbert, S., Salles, B., Valet, P., & Muller, C. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.101 · Cited by 140
Lederle, W., Depner, S., Schnur, S., Obermueller, E., Catone, N., Just, A., Fusenig, N. E., & Mueller, M. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25621 · Cited by 140
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
Silverman, J., Lu, Q., Bakker, A., To, W., Duguay, A. N., Alba, B. M., Smith, R., Rivas, A., Li, P., Le, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1166 · Cited by 137
Jing, N., Li, Y., Xiong, W., Sha, W., Jing, L., & Tweardy, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4041 · Cited by 132
Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia.
Ando, K., Takahashi, F., Motojima, S., Nakashima, K., Kaneko, N., Hoshi, K., & Takahashi, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2020 · Cited by 131
Rational design of a receptor super‐antagonist of human interleukin‐6.
Savino, R., Ciapponi, L., Lahm, A., Demartis, A., Cabibbo, A., Toniatti, C., Delmastro, P., Altamura, S., & Ciliberto, G. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06931.x · Cited by 127
Ataie-Kachoie, P., Pourgholami, M., & Morris, D. (2013) · Cytokine & growth factor reviews · doi:10.1016/j.cytogfr.2012.09.001 · Cited by 123
Yang, F., Brown, C. E., Buettner, R., Hedvat, M., Starr, R., Scuto, A., Schroeder, A., Jensen, M. C., & Jove, R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0947 · Cited by 121
Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
Ando, K., Takahashi, F., Kato, M., Kaneko, N., Doi, T., Ohe, Y., Koizumi, F., Nishio, K., & Takahashi, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102436 · Cited by 120
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Fulciniti, M., Hideshima, T., Vermot‐Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E., Wang, W., PRABHALA, R. H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1483 · Cited by 119
Goumas, F. A., Holmer, R., Egberts, J. D., Gontarewicz, A., Heneweer, C., Geisen, U. M., Hauser, C., Mende, M., Legler, K., Röcken, C., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29445 · Cited by 115
Xu, S., Grande, F., Garofalo, A., & Neamati, N. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1082 · Cited by 112
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106
A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130
Hong, S., Choi, J. H., Lee, S. Y., Park, Y.-H., Park, K.-Y., Lee, J. Y., Kim, J., Gajulapati, V., Goo, J.-I., Singh, S., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402908 · Cited by 101
Song, L., Smith, M. A., Doshi, P. D., Sasser, K., Fulp, W. J., Altiok, S., & Haura, E. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 100
Xu, Z.-H., Bouman-Thio, E., Comisar, C., Frederick, B., van Hartingsveldt, B., Marini, J., Davis, H., & Zhou, H.-H. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03964.x · Cited by 98
The immunobiology of myeloid-derived suppressor cells in cancer
Motallebnezhad, M., Jadidi‐Niaragh, F., Qamsari, E. S., Bagheri, S., Gharibi, T., & Yousefi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4477-9 · Cited by 95
Self-citationMease, P. J., Strand, V., Shalamberidze, L., Dimić, A., Raskina, T. A., Xu, L., Liu, Y., & Smith, J. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200704 · Cited by 95
Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo
Judd, L. M., Menheniott, T. R., Ling, H. Y., Jackson, C. B., Howlett, M., Kalantzis, A., Priebe, W., & Giraud, A. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095993 · Cited by 95
Kheshtchin, N., Arab, S., Ajami, M., Mirzaei, R., Ashourpour, M., Mousavi-Niri, N., Khosravianfar, N., Jadidi‐Niaragh, F., Namdar, A., Noorbakhsh, F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1879-5 · Cited by 94
Self-citationHuang, C., Yang, G., Jiang, T., Huang, K., Cao, J., & Qiu, Z. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-51 · Cited by 94
Selander, K. S., Li, L., Watson, L., Merrell, M. A., Dahmen, H., Heinrich, P. C., Müller‐Newen, G., & Harris, K. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2516 · Cited by 92
Chen, C., Loy, A., Cen, L., Chan, C., Hsieh, F.-C., Cheng, G., Wu, B., Qualman, S. J., Kunisada, K., Yamauchi‐Takihara, K., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-111 · Cited by 91
Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance.
Ghandadi, M., & Sahebkar, A. (2016) · Current pharmaceutical design · doi:10.2174/1381612822666151124234417 · Cited by 87
Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
Miura, T., Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Takahashi, H., Furuse, J., Inagaki, M., Higashi, S., Kato, H., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000335 · Cited by 85
Shibayama, O., Yoshiuchi, K., Inagaki, M., Matsuoka, Y., Yoshikawa, E., Sugawara, Y., Akechi, T., Wada, N., Imoto, S., Murakami, K., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.174 · Cited by 84
Singh, A., Purohit, A., Ghilchik, M., & Reed, M. J. (1999) · Endocrine-Related Cancer · doi:10.1677/erc.0.0060139 · Cited by 84
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
Hayashi, M., Rho, M., Enomoto, A., Fukami, A., Kim, Y.-P., Kikuchi, Y., Sunazuka, T., Hirose, T., Komiyama, K., & Ōmura, S. (2002) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.232562799 · Cited by 84
Pemmaraju, N., Kantarjian, H. M., Kadia, T. M., Cortes, J. E., Borthakur, G. M., Newberry, K. J., Garcia‐Manero, G., Ravandi, F., Jabbour, E. J., DellaSala, S. E., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.08.003 · Cited by 84
gp130: a promising drug target for cancer therapy
Xu, S., & Neamati, N. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.830105 · Cited by 83
Hunsucker, S. A., Magarotto, V., Kuhn, D. J., Kornblau, S. M., Wang, M. L., Weber, D. M., Thomas, S. K., Shah, J. J., Voorhees, P. M., Xie, H., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08533.x · Cited by 80
Coexpression of IL-6 and TNF-α: prognostic significance on breast cancer outcome
Tripsianis, G., PAPADOPOULOU, E., Anagnostopoulos, K. P., Botaitis, S., Katotomichelakis, M., Romanidis, Κ., Kontomanolis, E. N., Tentes, I. K., & Kortsaris, A. (2013) · Neoplasma · doi:10.4149/neo_2014_026 · Cited by 77
Jadidi-Niaragh, F., Atyabi, F., Rastegari, A., Mollarazi, E., Kiani, M., Razavi, A., Yousefi, M., Kheshtchin, N., Hassannia, H., Hadjati, J., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4732-0 · Cited by 77
Self-citationNarita, Y., Kitamura, H., Wakita, D., Sumida, K., Masuko, K., Terada, S., Nakano, K., & Nishimura, T. (2013) · Journal of Immunology · doi:10.4049/jimmunol.1103797 · Cited by 75
Immunotherapeutic approaches for cancer therapy: An updated review
Kazemi, T., Younesi, V., Jadidi‐Niaragh, F., & Yousefi, M. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1019669 · Cited by 73
Self-citationHudes, G., Tagawa, S., Whang, Y., Qi, M., Qin, X., Puchalski, T., Reddy, M., Cornfeld, M., & Eisenberger, M. (2013) · Investigational new drugs · doi:10.1007/s10637-012-9857-z · Cited by 71
Macciò, A., & Madeddu, C. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1080-7 · Cited by 70
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
Rosean, T. R., Tompkins, V. S., Tricot, G. J. K., Holman, C., Olivier, A. K., Zhan, F., & Janz, S. (2014) · Immunologic Research · doi:10.1007/s12026-014-8528-x · Cited by 70
Chevalier, S., Fourcin, M., Robledo, O., Wijdenes, J., Pouplard-Barthelaix, A., & Gascan, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.14764 · Cited by 70
Mechanisms of tumor cell resistance to the current targeted-therapy agents
Khamisipour, G., Jadidi-Niaragh, F., Jahromi, A. S., Zandi, K., & Hojjat-Farsangi, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5059-1 · Cited by 67
Self-citationInhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models
Sun, Y., Moretti, L., Giacalone, N. J., Schleicher, S. M., Speirs, C. K., Carbone, D. P., & Lü, B. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820d9d11 · Cited by 65
Hönemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dörken, B., & Bargou, R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1388 · Cited by 65
Yoshio‐Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A. V., Curiel, D. T., & Nishimoto, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3641 · Cited by 60
Myeloid-derived suppressor cells in B cell malignancies
Yazdani, Y., Mohammadnia‐Afrouzi, M., Yousefi, M., Anvari, E., Ghalamfarsa, G., Hassannia, H., Sadreddini, S., & Jadidi‐Niaragh, F. (2015) · Tumor Biology · doi:10.1007/s13277-015-4004-z · Cited by 58
Self-citationWang, D., Xu, J., Liu, B., He, X., Zhou, L., Hu, X., Qiao, F., Zhang, A., Xu, X., Zhang, H., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.162 · Cited by 57
Ishdorj, G., Johnston, J. B., & Gibson, S. B. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0550 · Cited by 57
Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma
Fontanini, G., Campani, D., Roncella, M., Cecchetti, D., Calvo, S., Toniolo, A., & Basolo, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690394 · Cited by 55
Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions
Jadidi-Niaragh, F., Ghalamfarsa, G., Yousefi, M., Tabrizi, M., & Shokri, F. (2013) · Tumor Biology · doi:10.1007/s13277-013-0832-x · Cited by 52
Self-citationEnomoto, A., Rho, M., Fukami, A., Hiraku, O., Komiyama, K., & Hayashi, M. (2004) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2004.08.196 · Cited by 50
IL-6 variant is associated with metastasis in breast cancer patients
Abana, C. O., Bingham, B. S., Cho, J. H., Graves, A. J., Koyama, T., Pilarski, R., Chakravarthy, A. B., & Xia, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181725 · Cited by 47
Oguro, T., Ishibashi, K., Sugino, T., Hashimoto, K., Tomita, S., Takahashi, N., Yanagida, T., Haga, N., Aikawa, K., Suzutani, T., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.038 · Cited by 47
Sommer, J., Effenberger, T., Volpi, E., Waetzig, G. H., Bernhardt, M., Suthaus, J., Garbers, C., Rose‐John, S., Floss, D. M., & Scheller, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.349167 · Cited by 46
Yu, K.-D., Di, G. H., Fan, L., Chen, A.-X., Yang, C., & Shao, Z. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0706-5 · Cited by 45
Siltuximab: First Global Approval
Markham, A., & Patel, T. (2014) · Drugs · doi:10.1007/s40265-014-0249-x · Cited by 44
Cavarretta, I. T. R., Neuwirt, H., Zaki, M. H., Steiner, H., Hobisch, A., Nemeth, J. A., & Čulig, Z. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_56 · Cited by 43
Hosseini, F., Hassannia, H., Mahdian-Shakib, A., Jadidi-Niaragh, F., Enderami, S. E., Fattahi, M., Anissian, A., Mirshafiey, A., & Kokhaei, P. (2017) · Cancer Medicine · doi:10.1002/cam4.1013 · Cited by 41
Self-citationSeavey, M. M., Lu, L. D., Stump, K. L., Wallace, N. H., Hockeimer, W., O’Kane, T. M., Ruggeri, B., & Dobrzański, P. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0951 · Cited by 41
The role of natural killer T cells in B cell malignancies
Ghalamfarsa, G., Hadinia, A., Yousefi, M., & Jadidi‐Niaragh, F. (2013) · Tumor Biology · doi:10.1007/s13277-013-0743-x · Cited by 41
Self-citationBinding of madindoline A to the extracellular domain of gp130.
Saleh, A. Z., Greenman, K. P., Billings, S. B., Vranken, D. V. V., & Krolewski, J. (2005) · Biochemistry · doi:10.1021/bi050439+ · Cited by 39
Song, Y., Santen, R. J., Wang, J., & Yue, W. (2012) · Endocrinology · doi:10.1210/en.2012-2038 · Cited by 39
Yu, X., He, L., Cao, P., & Yu, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128406 · Cited by 39
Casneuf, T., Axel, A., King, P., Alvarez, J., Werbeck, J., Verhulst, T., Verstraeten, K., Hall, B., & Sasser, A. (2016) · Breast Cancer · doi:10.2147/bctt.s92414 · Cited by 39
Chien, C.-M., Lin, K., Su, J.-C., Chuang, P.-W., Tseng, C.-H., Chen, Y.-L., Chang, L., & Lin, S. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.030 · Cited by 35
Hayashi, M., Rho, M., Fukami, A., Enomoto, A., Nonaka, S., Sekiguchi, Y., Yanagisawa, T., Yamashita, A., Nogawa, T., Kamano, Y., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036137 · Cited by 28
AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer
Kobayashi, A., 谷崎, 優., Kimura, A., Ishida, Y., Nosaka, M., Toujima, S., Kuninaka, Y., Minami, S., Ino, K., & Kondo, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.039 · Cited by 27
A novel small-molecule inhibitor of IL-6 signalling.
Zinzalla, G., Haque, M. R., Basu, B., Anderson, J., Kaye, S., Haider, S., Hasan, F., Antonow, D., Essex, S., Rahman, K., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.117 · Cited by 23
Markkula, A., Simonsson, M., Ingvar, C., Rose, C., & Jernström, H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-759 · Cited by 22
Chari, A., Pri‐Chen, H., & Jagannath, S. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.12.010 · Cited by 22
The Associations between Immunity-Related Genes and Breast Cancer Prognosis in Korean Women
Choi, J., Song, N., Han, S., Chung, S., Sung, H., Lee, J.-Y., Jung, S., Park, S.-K., Yoo, K., Han, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103593 · Cited by 17
Sommer, J., Effenberger, T., Volpi, E., Waetzig, G. H., Bernhardt, M., Suthaus, J., Garbers, C., Rose-John, S., Floss, D., & Scheller, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.349167 · Cited by 14
Green light for Janssen's IL-6 blocker
Mullard, A. (2014) · Nature Biotechnology · doi:10.1038/nbt0714-607b · Cited by 6
Research works printed but not linked: 5
- Kozlowski, 2003, Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients, Rocz. Akad. Med. Bialymst., 48, 82
- Jiang, 2011, Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells, Anticancer Res., 31, 2899
- Chiu, 1996, Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines, Clin. Cancer Res., 2, 215
- Sa-Nguanraksa, 2016, Association of Estrogen Receptor Alpha and Interleukin 6 Polymorphisms with Lymphovascular Invasion, Extranodal Extension, and Lower Disease-Free Survival in Thai Breast Cancer Patients, Asian Pac. J. Cancer Prev., 17, 2935
- Tawara, 2011, Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies, Cancer Manag. Res., 3, 177
Cited by
Sorted by citations
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 728
“In the TME, IL-6 trans-signaling promotes stable binding of GP130 and a soluble form of the IL-6 receptor (sIL-6R) to IL-6 [106].”
BackgroundInfluentialInterleukin-6: A Masterplayer in the Cytokine Network
Uciechowski, P., & Dempke, W. C. M. (2020) · Oncology · doi:10.1159/000505099 · Cited by 484
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 454
C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
Hart, P. C., Rajab, I. M., Alebraheem, M., & Potempa, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595835 · Cited by 291
Metadata
- Authors
- Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., & Jadidi-Niaragh, F.
- Affiliations
- Tabriz University of Medical Sciences (IR)
- University of Maragheh (IR)
- Yasuj University of Medical Sciences (IR)
- Alborz University of Medical Sciences (IR)
- ORCID
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 108
- Pages
- 1415-1424
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W2894776217
- Cited by
- 303
- References
- 136
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 60 · 2022: 67 · 2021: 41 · 2020: 39 · 2019: 9 · 2018: 1
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Biomedicine & Pharmacotherapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute for Medical Research Development
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- interleukin-6, IL-6 signaling, breast cancer, tumor microenvironment, chronic inflammation, cancer-associated fibroblasts, chemoresistance, radioresistance (biology), metastasis, immunopathogenesis, combination therapy
- MeSH terms
- Janus Kinase Inhibitors, Interleukin-6 Inhibitors, Antibodies, Monoclonal, Breast Neoplasms, Female, Humans, Signal Transduction, Interleukin-6, Receptors, Interleukin-6, Tumor Microenvironment, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
